KEY DETAILS
A review found tirzepatide eased sleep apnea, a common cause of severe snoring. The US approved it for this use in 2024.
Novo Nordisk launched the Wegovy pill in Germany on September 1, the first EU country to get it.
UC Berkeley researchers found a compound, TOFA, that cut fat in obese mice by raising how much energy their cells burn, not by lowering appetite. It has not been tested in people.
GLP-1 growth may lift Establishment Labs, a breast implant maker, per TD Securities.
A new review looks at how well tirzepatide treats obstructive sleep apnea, a common cause of severe snoring. That use is not new: the FDA approved tirzepatide, as Zepbound, for sleep apnea in adults with obesity in December 2024. The review lands the same week Novo Nordisk launched the Wegovy pill in Germany, and alongside a mouse study of a compound that cut fat without suppressing appetite. For anyone tracking this class of drugs, either as a patient or an investor, today's developments touch on the drugs' health effects, their reach, and their competitors.
The review gathers results on tirzepatide and obstructive sleep apnea, a condition in which the airway keeps closing during sleep and which often shows up as loud snoring. In the trials behind the 2024 approval, up to about half of patients on tirzepatide reached remission or mild sleep apnea without symptoms after a year. Sleep apnea is linked to daytime fatigue and long-term heart strain, so for people whose weight is affecting their sleep, this is a use worth raising with a doctor.
Novo Nordisk launched the Wegovy pill in Germany on September 1, the first country in the European Union to get it. Injectable Wegovy was already sold in Germany, so this adds a daily pill to a market where the weekly shot is available. Novo Nordisk has faced growing competition from Eli Lilly's Zepbound in the U.S., so building volume in Europe gives the company a way to diversify its revenue rather than lean on a single region. For patients in Germany, the launch means a pill option alongside the weekly injection.
Separately, UC Berkeley researchers reported a compound called TOFA that cut fat in obese mice by raising how much energy their cells burn, instead of lowering appetite the way GLP-1 drugs do. A treatment that works without reducing food intake would be a different approach, and could appeal to patients who struggle with appetite suppression itself. The work has only been done in mice, and the researchers have not yet tested whether TOFA is safe or works in people.
The ripple effects of widening GLP-1 use are reaching into adjacent businesses as well. TD Securities said today that Establishment Labs, a breast implant maker, may be positioned to benefit as GLP-1 use continues to rise, since the firm is set to expand its breast implant business in the U.S. The connection reflects a pattern analysts have noted: as patients lose significant weight, some seek cosmetic procedures to address changes in body shape that weight loss can bring. For anyone watching the GLP-1 drug class from an investment angle, this kind of secondary effect is a reminder that the financial impact of these medications extends well past the companies that manufacture them.
The common thread across today's developments is that the effects of GLP-1 drugs keep extending past their original purpose, from sleep quality to international markets to companies that make cosmetic products. Patients should raise any new symptom or benefit, such as changes in snoring, with their own doctor rather than draw broad conclusions from a single review. Anyone following this drug class from a financial standpoint might do well to track two things: how quickly newer compounds without appetite suppression move through development, and how established drugmakers like Novo Nordisk perform as they enter new countries. Both will shape how this drug class evolves over the coming years.
Read this on GLP-1 Nation: https://glp1nation.com/edition/37
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.